Akeso Says NMPA Approved SNDA For Cadonilimab

Published on 05/06/2025 at 06:29

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Akeso, Inc.

Nomura Adjusts Akeso's Price Target to HK$120.64 From HK$99.66, Keeps at Neutral	18/07	MT
Akeso, Inc. Announces First Patient Enrolled in the Phase III Trial (AK112-312/HARMONi-GI6) of Ivonescimab for First-Line Treatment of Advanced Metastatic Colorectal Cancer	16/07	CI
Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports	03/07	RE
Akeso's First Bispecific Adc (Trop2/Nectin4 Adc) Enters Clinical Trials, Strengthening Leadership in 'Io+Adc'2.0 Strategy	03/07	CI
Akeso, Inc. Presents Subgroup Analysis Data from the Phase III Company-16 Trial	16/06	CI
TransThera Sciences Launches Up to HK$201 Million IPO in Hong Kong	13/06	MT
Akeso Gets China Nod for Cervical Cancer Drug	05/06	MT
Akeso Says NMPA Approved SNDA For Cadonilimab	05/06	RE
Akeso Hits Snag with Less Favorable Clinical Trial Data for Lung Cancer Treatment; Shares Rise 7%	03/06	MT
Akeso Grants Share Options, Restricted Share Units	26/05	MT
Nomura Downgrades Akeso to Neutral From Buy, Adjusts Price Target to HK$99.66 From HK$75.14	28/04	MT
Akeso Gets China Nod for Lung Cancer Drug Indication	28/04	MT
Akeso, Inc. Announces the Global First-In-Class Pd-1/Vegf Bi-Specific Antibody,Ivonescimab, Has Received Approval from the National Medical Products Administration	27/04	CI
Akeso, Inc. Receives Approval for ivonescimab by the Chinese Health Authorities	26/04	CI
Summit Therapeutics Gets Approval From China's Health Authority for Second Use of Ivonescimab	26/04	MT
Akeso, Inc. Announces Its Globally First-In-Class PD-1/VEGF Bispecific Antibody, Ivonescimab, Received Approval from the National Medical Products Administration	25/04	CI
US FDA Approves Nasopharyngeal Carcinoma Drug	25/04	MT
Akeso Says FDA Approved Anniko (Penpulimab-Kcqx, Pd-1) In Two Indications	25/04	RE
Akeso, Inc. Announces FDA Approval for Penpulimab-kcqx in Two BLA Indications for Comprehensive Treatment of Advanced Nasopharyngeal Carcinoma	25/04	CI
Summit Therapeutics Says Phase 3 Cell Lung Cancer Trial Met Primary Endpoint; Shares Rise Pre-Bell	23/04	MT
Summit Therapeutics Inc. Announces Phase Iii Clinical Trial, Harmoni-6	23/04	CI
Akeso's Lung Cancer Drug Meets Primary Endpoints in China Phase 3 Trial; Shares Rise 5%	23/04	MT
Akeso, Inc. Announces Its Global First-In-Class Pd-1/Vegf Bispecific Antibody, in Combination with Chemotherapy	23/04	CI
Akeso, Inc. Announces Positive Results in Phase III Clinical Trial (AK112-306/HARMONi-6) for First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer	23/04	CI
Akeso's NDA for Plaque Psoriasis Drug Gets China Nod	22/04	MT